REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

• Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.
• Regeneron will lower the Medicaid prices of its products to match those in other developed nations.
• REGN commits $9 billion in domestic R&D and manufacturing capacity.

Regeneron Pharmaceuticals (REGN) on Thursday became the 17th and the final biopharma firm to sign Trump’s drug pricing agreement, which is a pledge to lower the cost of current and future life-altering medications. 

The deal commits Regeneron to lower prices on its current and future medicines for Medicaid patients to match the lowest rates paid in other developed nations. As part of the pact, the company will sell its blockbuster cholesterol drug Praluent for $225 — down from roughly $537 — through the TrumpRx.gov direct-to-consumer platform.

"For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation — effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.

 “Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation.” 

Regeneron is the last of the original 17 pharmaceutical companies that received letters from Trump in July 2025, urging them to lower drug prices in the U.S. to levels paid by other developed nations. Companies that have already signed similar agreements include AbbVie, Amgen, AstraZeneca, Eli Lilly, GSK and Sanofi.

Otarmeni Approval And Sale

REGN on Thursday also announced that its gene therapy for genetic hearing loss, Otarmeni, received accelerated approval from the U.S. Food and Drug Administration (FDA), and the firm will be providing the treatment free of cost to Americans. 

As part of the MFN agreement, Regeneron will not be subject to future pricing mandates and will receive three years of tariff relief through an agreement with the U.S. Department of Commerce. The company also committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.

What is Trump’s MFN

The Most-Favored-Nation (MFN) policy is a signature healthcare initiative of the Trump administration designed to ensure that Americans do not pay more for prescription drugs than patients in other developed countries.

Participating companies agree to offer deeply discounted pricing on drugs supplied to Medicaid and through the TrumpRx.gov platform.

Retail Take

Retail sentiment on Stocktwits around REGN stock was ‘bullish’ with ‘high’ message volumes. 

One user highlighted he was bullish on REGN and UNH shares. 

https://stocktwits.com/DrAzevedo/message/616338118

The stock lost 0.8% year-to-date.

For updates and corrections, email newsroom[at]stocktwits[dot]com.